Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Administration of UI111 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| UI111 | EXPERIMENTAL | Test |
| UIC202006 | ACTIVE_COMPARATOR | Reference |
| Name | Type | Description |
|---|---|---|
| Administration of UI111 | DRUG | 1cap, once a day |
| Administration of UIC202006 | DRUG | 1cap, once a day |
Inclusion Criteria: * Subjects who are at least 19 years of age at the time of the screening visit. * Subjects who weigh at least 50 kg (at least 45 kg for females) and have a body mass index (BMI) between 18.0 and 30.0 kg/m², inclusive, at the time of the screening visit. ☞ BMI (kg/m²) = body weig...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
Administration of UI111 is an investigational small molecule being developed for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Administration of UI111 is being developed by United Therapeutics Corporation, a publicly traded company listed on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of this investigational drug.
Administration of UI111 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and pharmacokinetic profile in humans.
Administration of UI111 has one completed Phase 1 clinical trial registered under NCT07691268. This study evaluated the safety and pharmacokinetics of UI111 and UIC202006 under fed conditions in 44 participants with dyslipidemia in South Korea. The trial was randomized and active-controlled.
Administration of UI111 is a small molecule being developed for dyslipidemia. The specific molecular target or mechanism of action has not been disclosed in the available clinical trial information. Further research is needed to determine how this investigational drug exerts its effects on lipid levels.